Deltorphin
Deltorphin is a family of amphibian-derived opioid heptapeptides isolated from the skin of Phyllomedusa bicolor (giant monkey frog) that display the highest known selectivity for the delta-opioid receptor (DOR). The incorporation of a D-amino acid at position 2 confers exceptional enzymatic stability and receptor selectivity, making deltorphins essential research tools for delta-opioid pharmacology and potential templates for non-addictive analgesics.
Overview
The deltorphins were discovered in the late 1980s by Vittorio Erspamer and colleagues during their systematic investigation of bioactive peptides in amphibian skin secretions. Erspamer, who had previously discovered caerulein, physalaemin, and bombesin from frog skin, identified deltorphin (initially named dermenkephalin) as the most delta-selective opioid peptide known (Erspamer et al., 1989). The subsequent discovery of deltorphin II by Kreil et al. (1989) provided an even more selective DOR agonist and revealed the genetic basis for D-amino acid incorporation in vertebrates (Kreil et al., 1989).
The deltorphins are encoded by conventional genes, but the D-amino acid at position 2 is generated post-translationally by a specific isomerase enzyme, making Phyllomedusa bicolor one of the few vertebrates known to enzymatically produce D-amino acids in peptides. This discovery had broad implications for peptide biology and challenged the assumption that animal peptides contain exclusively L-amino acids.
The deltorphins have become indispensable pharmacological tools for studying delta-opioid receptor function, and their demonstration that DOR-selective analgesia can occur with reduced mu-opioid side effects has fueled interest in delta-receptor-targeted therapeutics for pain management.
Mechanism of Action
Deltorphins produce their effects through highly selective delta-opioid receptor activation:
- Delta-opioid receptor binding: Deltorphin II binds DOR with Ki ~0.16 nM and approximately 10,000-fold selectivity over MOR. Deltorphin I has slightly lower selectivity (~4,000-fold). Both are full agonists at DOR. The D-amino acid at position 2 is critical for delta-selectivity — replacement with the L-isomer dramatically shifts selectivity toward mu-receptors (Lazarus et al., 1999).
- Gi/Go-coupled signaling: DOR activation inhibits adenylyl cyclase, opens GIRK channels, and modulates voltage-gated calcium channels, producing neuronal inhibition in pain pathways. DOR shares the basic opioid signaling cascade with MOR but differs in downstream effector coupling and trafficking.
- Spinal analgesia: Intrathecal deltorphin produces dose-dependent antinociception, primarily through DOR on primary afferent terminals and intrinsic dorsal horn neurons. DOR is expressed on large-diameter (A-beta/A-delta) as well as small-diameter (C) fiber terminals, producing a broader sensory modulation profile than MOR agonists (Cahill et al., 2007).
- Supraspinal analgesia: ICV deltorphin produces analgesia through DOR in the periaqueductal gray, rostral ventromedial medulla, and amygdala. The supraspinal analgesic effect is generally less potent than equimolar mu-agonists but involves less respiratory depression.
- Inflammatory pain modulation: DOR expression and function are upregulated during chronic inflammatory states. Deltorphin's analgesic efficacy increases in models of chronic inflammation, suggesting that DOR-targeted analgesics may be particularly effective for inflammatory pain conditions (Gendron et al., 2007).
Reconstitution Calculator
Research
Delta-Opioid Selectivity and Pain
Deltorphins have been instrumental in establishing that selective DOR activation produces meaningful analgesia. While early opioid pharmacology focused on mu-receptors (morphine's primary target), deltorphin studies demonstrated that DOR agonism produces antinociception in thermal, mechanical, and chemical pain models, with a pharmacological profile distinct from mu-agonist analgesia. Importantly, DOR-mediated analgesia appears to be most pronounced in chronic pain states (inflammatory, neuropathic) where DOR surface expression is upregulated, compared to acute pain where MOR predominates (Cahill et al., 2007).
Antinociception Without Mu-Opioid Side Effects
A primary attraction of deltorphin pharmacology is evidence that DOR-selective analgesia produces fewer mu-associated side effects:
- Respiratory depression: Deltorphin produces significantly less respiratory depression than equianalgesic morphine doses. DOR knockout studies confirm that delta-receptors contribute minimally to opioid-induced respiratory depression (Su et al., 1998).
- Constipation: DOR agonism produces less inhibition of GI transit than MOR agonism
- Reward/addiction: DOR agonists generally show lower reinforcing efficacy than mu-agonists in self-administration paradigms, though the relationship between DOR and reward is complex
- Tolerance: Chronic deltorphin administration produces tolerance, but cross-tolerance with morphine is incomplete, suggesting potential for rotation strategies
Potential for Non-Addictive Pain Relief
The reduced addiction liability of delta-selective opioids compared to mu-agonists has made deltorphins important research tools in the search for non-addictive analgesics. DOR agonists show lower self-administration rates and reduced conditioned place preference compared to morphine in most (though not all) studies. The combination of analgesic efficacy (particularly in chronic pain), reduced respiratory depression, and lower abuse potential positions DOR-selective compounds as promising therapeutic candidates (Pradhan et al., 2011).
Anxiolytic and Antidepressant Properties
Beyond analgesia, DOR activation by deltorphin produces anxiolytic and antidepressant-like effects in preclinical models. DOR knockout mice display increased anxiety and depressive behavior, and deltorphin reverses stress-induced depressive phenotypes. This emotional modulation, mediated through DOR in the amygdala and hippocampus, adds therapeutic value to the delta-opioid approach and may distinguish it from mu-opioid strategies that can worsen mood disorders with chronic use (Filliol et al., 2000).
D-Amino Acid Incorporation
The natural occurrence of D-Met (deltorphin I) and D-Ala (deltorphin II) at position 2 was a landmark discovery in peptide biology. The D-amino acid is encoded as L-amino acid in the prodeltorphin gene and is converted post-translationally by a specific isomerase in frog skin. This enzymatic L-to-D conversion:
- Confers resistance to aminopeptidase degradation (dramatically extending half-life)
- Introduces a conformational constraint that favors DOR over MOR binding
- Provided the first evidence of enzymatic D-amino acid production in vertebrate peptides (Kreil, 1997)
This discovery stimulated research into D-amino acid incorporation as a general strategy for improving peptide drug stability and has influenced the design of analogs across multiple therapeutic peptide classes.
Delta-selective opioid antinociception
Deltorphins (deltorphin I, deltorphin II / [D-Ala2]deltorphin II) are amphibian-derived heptapeptides containing a D-amino acid that confers the greatest delta opioid receptor affinity and selectivity of any known natural compound. They are widely used to dissect the delta receptor's role in pain control.
- Naturally occurring D-Ala2 residue confers exceptional delta-receptor selectivity
- Potent supraspinal and spinal antinociception in rodent models
- Delta agonists show relatively favorable side-effect profiles versus mu agonists in preclinical work
Peripheral and neuropathic pain targeting
Delta agonists including deltorphin II are more effective in persistent inflammatory and neuropathic pain than in acute nociception, and peripheral delta receptors on sensory neurons offer a route to analgesia with reduced central adverse effects.
- Functional delta opioid receptors are upregulated on nociceptors after nerve injury (PMID 32848761)
- Peripheral deltorphin II reduces mechanical nociceptor responsiveness following injury
- Delta activation modulates affective components of chronic pain
Safety Profile
Deltorphins are research tools not used clinically. Preclinical safety observations include:
- Analgesia: Effective via central routes (ICV, intrathecal); limited systemic efficacy due to poor BBB penetration of native peptides
- Respiratory depression: Significantly less than equianalgesic mu-agonist doses; DOR contributes minimally to respiratory depression
- Convulsions: High-dose DOR agonists can produce seizures (proconvulsant effect), which represents the primary safety concern for delta-selective compounds. This is a class effect of DOR agonists and has been a major obstacle to clinical development (Comer et al., 1993)
- Cardiovascular: Hypotension and bradycardia at high doses
- GI motility: Reduced transit, but less than equianalgesic morphine
- Tolerance: Develops with repeated administration
- Kambo/sapo caution: Use of crude Phyllomedusa bicolor skin secretions carries risks of severe nausea, vomiting, tachycardia, hypotension, and rare case reports of death; this is unrelated to purified deltorphin research
Pharmacokinetic Profile
Quick Start
- Route
- Research: intrathecal, intracerebroventricular
Molecular Structure
- Formula
- C44H62N10O10S2
- Weight
- 955.2 Da
- PubChem CID
- 3035060
- Exact Mass
- 954.4092 Da
- LogP
- -0.8
- TPSA
- 381 Ų
- H-Bond Donors
- 11
- H-Bond Acceptors
- 14
- Rotatable Bonds
- 29
- Complexity
- 1600
Identifiers (SMILES, InChI)
InChI=1S/C44H62N10O10S2/c1-25(2)18-34(42(62)50-32(15-17-66-4)40(60)51-33(38(46)58)22-37(56)57)52-44(64)36(21-28-23-47-24-48-28)54-43(63)35(20-26-8-6-5-7-9-26)53-41(61)31(14-16-65-3)49-39(59)30(45)19-27-10-12-29(55)13-11-27/h5-13,23-25,30-36,55H,14-22,45H2,1-4H3,(H2,46,58)(H,47,48)(H,49,59)(H,50,62)(H,51,60)(H,52,64)(H,53,61)(H,54,63)(H,56,57)/t30-,31+,32-,33-,34-,35-,36-/m0/s1
BHSURCCZOBVHJJ-NWOHMYAQSA-NResearch Indications
Primary Research Areas
Highly selective delta opioid receptor agonist used to probe delta-mediated antinociception, with particular activity in persistent inflammatory and neuropathic pain models.
Benchmark natural delta-selective agonist for receptor characterization and signaling studies.
Research Protocols
intrathecal Injection
- Spinal analgesia: Intrathecal deltorphin produces dose-dependent antinociception, primarily through DOR on primary afferent terminals and intrinsic dorsal horn neurons.
intracerebroventricular Injection
Administered via intracerebroventricular.
Interactions
Peptide Interactions
Deltorphin is a highly selective delta-opioid receptor agonist. Delta and mu receptors form heterodimers and exhibit complex cross-talk. Delta agonists can modulate mu-opioid tolerance development, and co-administration may alter the analgesic profile and side effect spectrum of mu agonists. (Gomes et al., 2004, J Neurosci)
Quality Indicators
What to look for
- Extensive peer-reviewed research base
Frequently Asked Questions
References (15)
- [1]Erspamer V et al Deltorphins: a family of naturally occurring peptides with high affinity and selectivity for delta opioid binding sites Proc Natl Acad Sci U S A (1989)
- [5]Cahill CM et al Up-regulation and trafficking of delta opioid receptor in a model of chronic inflammation Pain (2007)
- [7]Su YF et al Selective involvement of mu-opioid receptors in opioid-induced respiratory depression J Pharmacol Exp Ther (1998)
- [2]Kreil G et al Deltorphin, a novel amphibian skin peptide with high selectivity and affinity for delta opioid receptors Eur J Pharmacol (1989)
- [3]
- [4]Lazarus LH et al Deltorphins: naturally occurring peptides with delta opioid receptor selectivity Int J Pept Protein Res (1999)
- [6]Gendron L et al Morphine and pain-related stimuli enhance cell surface availability of somatic delta-opioid receptors in rat dorsal root ganglia J Neurosci (2007)
- [8]Pradhan AA et al In vivo delta opioid receptor internalization controls behavioral effects of agonists PLoS One (2011)
- [9]Filliol D et al Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses Nat Genet (2000)
- [10]Gomes I et al A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia Proc Natl Acad Sci U S A (2004)
- [11]Comer SD et al Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice J Pharmacol Exp Ther (1993)
- [12]Improta G, Broccardo M Antinociceptive effects of [D-Ala2]deltorphin II, a highly selective delta agonist in vivo European Journal of Pharmacology (1990)
→ [D-Ala2]deltorphin II was ~13-fold more potent than the reference delta agonist DPDPE and roughly equipotent with morphine after i.c.v. dosing, supporting a delta-receptor contribution to supraspinal antinociception.
- [13]Sakurada S, Watanabe H, Mizoguchi H, et al. Spinal antinociceptive effects of [D-Ala2]deltorphin II, a novel and highly selective delta-opioid receptor agonist Peptides (1992)
→ Deltorphins I and II, isolated from Phyllomedusa bicolor skin, show higher delta-receptor affinity and selectivity than any other known natural compound and produce dose-related spinal antinociception.
- [14]Scherrer G, Befort K, Contet C, Becker J, Matifas A, Kieffer BL The delta agonists DPDPE and deltorphin II recruit predominantly mu receptors to produce thermal analgesia: a parallel study of mu, delta and combinatorial opioid receptor knockout mice European Journal of Neuroscience (2004)
→ Using opioid receptor knockout mice, thermal analgesia from deltorphin II was largely mu-dependent, while delta receptors alone produced weak but significant mu-independent antinociception, refining the interpretation of delta-agonist pharmacology.
- [15]Joukal M, Vulchanova L, Huffman C, Dubový P, Honda CN Peripheral Deltorphin II Inhibits Nociceptors Following Nerve Injury Frontiers in Pharmacology (2020)
→ Provides direct evidence for functional delta opioid receptors on cutaneous mechanical nociceptors after nerve injury, where peripheral deltorphin II reduced nociceptor responsiveness, supporting peripherally restricted delta agonists for neuropathic pain.
DECAPEPTIDE-12
Decapeptide-12 is a ten-residue synthetic oligopeptide with potent anti-tyrosinase activity, studied primarily for its ability to reduce melanin production and
Demoxytocin
Demoxytocin is a synthetic analog of the neuropeptide oxytocin, modified by the removal of the N-terminal amino group to increase its resistance to enzymatic de